To the Editor: A 63-year-old Chinese woman was presented to West China Hospital complaining of dry eyes and mouth for 40 years and repeated epistaxis for 2 years. She was diagnosed with iron deficiency anemia (IDA) 9 years ago, and primary Sjögren's syndrome (pSS) and primary biliary cirrhosis (PBC) 3 years ago. In the past 3 years, she was diagnosed and treated in West China Hospital for severe IDA. Repeated red blood cell suspension and iron sucrose supplementation showed no effect. She received gastroscopy 2 years ago and telangiectasia in the antrum was found. Thus, two argon plasma coagulations (APCs) were given. She had no abnormal family history. Physical examinations on admission showed tongue telangiectasia and dry eyes and mouth [ Figure 1A ]. Dental caries could be seen in the mouth. The skin and palpebral conjunctiva were pale. Complete blood counts showed microcytic hypochromic anemia. The increase of alkaline phosphatase, soluble transferrin receptor and total iron binding capacity were detected. Meanwhile, the decrease of serum iron, transferrin saturation and ferritin were noticed. And fecal occult blood was positive. Antinuclear antibody titer was 1:1000. Anti-SS-related antigen A (SSA) antibody and antimitochondrial type 2 antibody (AMA-M2) were positive. Schirmer test showed 3 mm and 4 mm per 5 min in the left and right eye respectively. Urine routine, glucose-6phosphate dehydrogenase, Coombs test and erythrocyte incubation osmotic fragility test were normal. Abdominal color Doppler ultrasound revealed cirrhosis, splenomegaly, ascites, abnormal hepatic veins and extrahepatic portal vein thickening. While, biliary color Doppler ultrasound showed no biliary tract stenosis. Bone marrow aspiration and biopsy suggested that erythroid hyperplasia was active, while iron stain disappeared. Therefore, she accepted gastrointestinal endoscopy and double-balloon enteroscopy after receiving red blood cell suspension and sucrose iron, which showed multiple telangiectasia of the antrum, jejunal, and colorectal [ Figure 1B ]. Thus, the reason of severe anemia was hereditary hemorrhagic telangiectasia (HHT). A small dosage of thalidomide (50 mg every night) was given. And she did not suffer from significant side effects. Symptoms of anemia and laboratory tests significantly improved and the amount of iron supplement decreased during the follow-up.
The pSS is a chronic autoimmune inflammatory disorder causing dryness of the eyes and mouth. [1] This patient suffered from dry eyes and mouth for more than 3 months, and Schirmer test and anti-SSA antibody were positive, so she was also diagnosed as pSS. PBC is characterized by an ongoing immunologic attack on the intralobular bile ducts that may eventually lead to cirrhosis and liver failure. [2] Mild anemia is one of the common complications of pSS. The cause of anemia in PBC patients is most likely related to gastrointestinal variceal bleeding or hypersplenism caused by portal hypertension. HHT is a rare hereditary disease with abnormal vascular dysplasia, which may easily lead to severe and even life-threatening hemorrhage. [3] The patient had no esophageal or gastric varices. Although she had splenomegaly and severe anemia, the platelet count was normal. Severe anemia caused directly by pSS and PBC should not be considered. Hemolytic anemia, aplastic anemia, and hematological malignancies were also excluded. IDA was diagnosed according to the laboratory tests. Although this patient's first-degree relatives had no history of HHT, she had repeated epistaxis, mucosal telangiectasia, and visceral lesions. Thus, the diagnosis of the patient was HHT, according to the diagnostic criteria. [4] Telangiectasia of HHT is characterized by dilatation of the lumen of the blood vessel and thinning of the vessel wall. The occurrence of vascular malformations in HHT patients can be attributed to decreased transforming growth factor-b activation and increased production of vascular endothelial growth factor, leading to separation of endothelial and peripheral wall cells. [5] We inferred that the increased portal pressure of PBC might aggravate telangiectasia in gastrointestinal tract.
Thalidomide regulates the expression of signaling pathway components involved in stimulating or inhibiting angiogenesis, which reduces bleeding in HHT patients by stimulating vascular maturation. [5] APC is currently the most effective therapy for telangiectasia combined with bleeding. However, two APCs were given 2 years ago which had no improvement that might be the reason of portal hypertension. The patient was now treated with thalidomide, anemia significantly improved.
In this case, pSS and PBC contributed to the reason of severe anemia in the beginning, and PBC might aggravate gastrointestinal bleeding of HHT to some extent. Background diseases might also affect the treatment and prognosis of HHT patients.
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